700125P
Avanti
DMHCA
Avanti Research™ - A Croda Brand 700125P, powder
Synonyme(s) :
N,N-dimethyl-3β-hydroxycholenamide
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Formule empirique (notation de Hill):
C26H43NO2
Numéro CAS:
Poids moléculaire :
401.63
Code UNSPSC :
12352211
Nomenclature NACRES :
NA.25
Produits recommandés
![23:2 Diyne PE [DC(8,9)PE] 1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-phosphoethanolamine, powder](/deepweb/assets/sigmaaldrich/product/images/228/422/4e95f75c-14fa-4117-a383-2eff73fa927f/640/4e95f75c-14fa-4117-a383-2eff73fa927f.jpg)
Essai
>99% (TLC)
Forme
powder
Conditionnement
pkg of 1 × 5 mg (700125P-5mg)
Fabricant/nom de marque
Avanti Research™ - A Croda Brand 700125P
Conditions d'expédition
dry ice
Température de stockage
−20°C
Description générale
N,N-dimethyl-3β-hydroxy-cholenamide (DMHCA) is a potent steroidal liver X receptor (LXR) ligand in vitro and in vivo. It is used to treat atherosclerosis.
N,N-dimethyl-3β-hydroxycholenamide (DHMCA) is a synthetic ligand for liver X receptor (LXR).
Application
DMHCA has been used as LXR activator to treat retinal endothelial cells in order to activate the sirtuin 1- liver X receptors (SIRT1-LXR) pathway.
It may be used as 3β-hydroxysterol-Δ24-reductase (DHCR24) inhibitor.
Actions biochimiques/physiologiques
N,N-dimethyl-3β-hydroxycholenamide (DHMCA) halts cholesterol biosynthesis by inhibiting 3β-hydroxysterol-Δ24-reductase (DHCR24) enzyme. It may serve as a therapeutic agent for treating atherosclerosis, age-related macular degeneration and diabetic retinopathy.
DMHCA (N,N-dimethyl-3β-hydroxycholenamide) is a synthetic oxysterol and is an agonist for liver X receptors (LXR). It promotes cholesterol transport, expression of adenosine triphosphate (ATP) binding cassette transporters. DMHCA suppresses the proinflammatory cytokines stimulation, induced by oxysterol.
Conditionnement
5 mL Amber Glass Screw Cap Vial (700125P-5mg)
Informations légales
Avanti Research is a trademark of Avanti Polar Lipids, LLC
Code de la classe de stockage
11 - Combustible Solids
Faites votre choix parmi les versions les plus récentes :
Certificats d'analyse (COA)
Lot/Batch Number
Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.
Si vous avez besoin d'assistance, veuillez contacter Service Clients
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor.
Quinet E M, et al.
Journal of Lipid Research, 45(10), 1929-1942 (2004)
The mechanism of diabetic retinopathy pathogenesis unifying key lipid regulators, sirtuin 1 and liver X receptor
Hammer SS, et al.
EBioMedicine, 22, 181-190 (2017)
Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein
Scoles DR, et al.
Gynecologic Oncology, 116(1), 109-116 (2010)
Synthetic LXR agonist attenuates plaque formation in apoE-/-mice without inducing liver steatosis and hypertriglyceridemia
Kratzer A, et al.
Journal of Lipid Research, 50(2), 312-326 (2009)
Nicole El-Darzi et al.
Frontiers in pharmacology, 9, 827-827 (2018-08-10)
N,N-dimethyl-3β-hydroxycholenamide (DMHCA) is an experimental pharmaceutical and a steroidal liver X receptor (LXR) agonist, which does not induce undesired hepatic lipogenesis. Herein, DMHCA was evaluated for its retinal effects on normal C57BL/6J and Cyp27a1-/-Cyp46a1-/- mice; the latter having higher retinal
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique